Core Insights - Haemonetics Corporation announced its financial results for the fourth quarter and fiscal year 2025, which ended on March 29, 2025 [1] - The company will host a conference call and webcast on May 8, 2025, at 8:00 a.m. ET to discuss the results and answer questions from investors and analysts [1][2] - Supplemental tables providing additional information on fiscal 2026 revenue growth guidance have been posted on the Investor Relations website [2] Company Overview - Haemonetics is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency [3] - The company offers innovative solutions for critical medical needs, including hospital technologies, plasma collection technologies, and products for blood centers [3]

With that in mind, let's delve into the average projections of some Haemonetics metrics that are commonly tracked and projected by analysts on Wall Street. Wall Street analysts expect Haemonetics (HAE) to post quarterly earnings of $1.22 per share in its upcoming report, which indicates a year-over-year increase of 35.6%. Revenues are expected to be $327.34 million, down 4.7% from the year-ago quarter. The consensus EPS estimate for the quarter has undergone a downward revision of 3.3% in the past 30 days, ...

Financial Results Announcement - Haemonetics Corporation plans to publish its fourth quarter and fiscal year 2025 financial results on May 8, 2025, at 6:00 am ET [1] - A conference call for investors and analysts will take place on the same day at 8:00 am ET to discuss the results and answer questions [1] Conference Call Access - Participants can access the conference call via teleconference after completing registration, which provides a dial-in number and personalized PIN [2] - It is recommended that participants join the call 10 minutes early, and a live webcast will be available on Haemonetics' investor relations website [2] - A replay of the conference call and webcast will be accessible for one year starting from May 8, 2025, at 11:00 am ET [2] Company Overview - Haemonetics is a global healthcare company focused on innovative medical products and solutions aimed at improving patient care and reducing healthcare costs [3] - The company's technology serves critical medical markets, including blood and plasma component collection, surgical suites, and hospital transfusion services [3]

Core Insights - Haemonetics Corporation's Hospital business recovery is expected to drive growth in upcoming quarters, supported by the strong uptake of the NexSys PCS system and overall financial stability [1][3][6] Financial Performance - In the past year, Haemonetics' shares have decreased by 14.5%, while the industry and S&P 500 have grown by 9% and 10%, respectively [2] - The company has a market capitalization of $3.26 billion and has beaten earnings estimates in three of the last four quarters, with an average surprise of 1.01% [2] - The Zacks Consensus Estimate for fiscal 2025 earnings has decreased by 0.2% to $4.54 per share, while the revenue estimate is $1.39 billion, indicating a 6.2% increase from the previous year [10] Business Segments - The Hospital business achieved a 24% increase in revenues in the third quarter of fiscal 2025, driven by strong market growth and share gains [4] - The Interventional Technologies business grew by 47% in the same quarter, with significant contributions from the Vascular Closure business and positive feedback for the Enzo ETM esophageal cooling device [5] Product Developments - The NexSys PCS system, which is FDA-cleared, aims to enhance plasma yield collections and improve productivity, with the proprietary Persona Technology increasing yield by 9% to 12% on average [6][7] - The rollout of the NexSys system is expected to drive meaningful improvements in 2025 as the transition from older devices continues [7] Market Challenges - Ongoing global geopolitical constraints and economic uncertainty are impacting operational results, with a 5.4% year-over-year increase in the cost of goods sold [8] - The competitive landscape poses challenges, particularly with slower-than-expected product adoption by key customers like the American Red Cross [9]

Core Insights - Haemonetics Corporation has announced changes to its Executive Leadership team, appointing Frank Chan as Executive Vice President and Chief Operating Officer, effective April 7, 2025, and Roy Galvin as Executive Vice President and Chief Commercial Officer, effective immediately [1][4] Group 1: Leadership Changes - Frank Chan will oversee research and development, regulatory affairs, global manufacturing, and supply chain operations, reporting to the President and CEO Chris Simon [2] - Roy Galvin, previously President of Global Plasma and Blood Center, will now manage the Global Hospital business and direct commercialization initiatives for the entire product portfolio [4] Group 2: Leadership Experience - Frank Chan brings over 25 years of experience in medical device and healthcare technology, having previously served as President of Acute Care & Monitoring at Medtronic, and held roles at Covidien and DePuy Orthopaedics [3] - Roy Galvin has over 25 years of experience in the global healthcare technology field, particularly in the Neuroscience and Orthopedic markets at Medtronic [4] Group 3: Company Strategy - Chris Simon emphasized that the addition of Chan and the expanded role for Galvin aligns with the company's long-range plan for growth and success [5]

Core Insights - Haemonetics Corporation will have its President and CEO, Chris Simon, participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on March 4, 2025 [1] - The event will be accessible via a live webcast on Haemonetics' Investor Relations website, with a replay available for 90 days post-event [2] - Haemonetics is a global healthcare company focused on innovative medical products and solutions aimed at improving patient care and reducing healthcare costs, particularly in blood and plasma collection, surgical suites, and hospital transfusion services [3]

Core Insights - Takeda has received EMA approval for a new 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) aimed at adolescents (aged 12 and above) and adult patients with Hereditary Angioedema (HAE) [1][5] - This new option enhances Takeda's commitment to the HAE community by providing individualized treatment solutions to alleviate the burden of HAE and improve patients' quality of life [1][2] Company Overview - Takeda is a leading biopharmaceutical company focused on creating better health outcomes and delivering life-transforming treatments across various therapeutic areas, including rare diseases [7] - The company emphasizes innovation and patient-centric solutions, particularly for underserved communities, and has a strong historical engagement in HAE treatment [2][7] Product Information - TAKHZYRO® is a fully human monoclonal antibody that targets plasma kallikrein, indicated for the routine prevention of recurrent HAE attacks in patients aged 2 years and older [4][6] - The newly approved 300 mg solution for injection in a pre-filled pen is designed for subcutaneous administration, allowing for self-administration or caregiver administration after proper training [4][8] Market Context - HAE is a rare genetic disorder affecting approximately 1 in 50,000 people globally, often under-recognized and under-treated [2][3] - The approval of the new administration option is expected to provide additional individualized treatment choices for HAE patients aged 12 years and older, addressing a significant unmet need in the market [2][5]

Core Viewpoint - CSL Behring K.K. has received approval from Japan's Ministry of Health, Labour and Welfare for ANDEMBRY® (garadacimab) Subcutaneous Injection 200mg Pens, marking a significant advancement in the management of hereditary angioedema (HAE) [1][3] Product Overview - ANDEMBRY is the first fully human monoclonal antibody in Japan designed to inhibit activated Factor XII (Factor XIIa), which is crucial in the angioedema attack process [2] - The product is approved for the prevention of acute attacks of HAE and is the first pre-filled pen for once-monthly subcutaneous administration for long-term prophylaxis [1][6] Clinical Significance - The approval is based on the efficacy and safety data from the pivotal international Phase 3 VANGUARD trial, which included HAE patients from Japan [4][6] - HAE is a rare, chronic, debilitating genetic disorder affecting approximately 430 diagnosed patients in Japan, with a global prevalence estimated at 1 in 50,000 people [3][4] Company Commitment - CSL has a 40-year commitment to HAE research and treatment optimization, with ANDEMBRY being the first approved recombinant monoclonal antibody developed entirely by CSL [3][5] - The company emphasizes its dedication to improving the lives of those with HAE, having supported this community for over four decades [6][9] Approval Timeline - ANDEMBRY has also received approvals in Australia, the United Kingdom, and the European Union, indicating a broad acceptance of the product in multiple markets [1][7]

Haemonetics Corporation (HAE) delivered third-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.19, which rose 14.4% year over year. The bottom line was on par with the Zacks Consensus Estimate. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.On a GAAP basis, EPS was 74 cents compared with 61 cents in the prior-year quarter.Following the earnings announcement, shares of HAE rose 0.02% in after-market trading yesterday. HAE’s Q3 RevenuesRevenues increased 2.7% to $348.5 milli ...

Financial Data and Key Metrics Changes - The company reported third quarter revenue of $349 million, reflecting a 4% growth on a reported basis and flat organic growth [7] - Adjusted earnings per share increased by 14% to $1.19, indicating meaningful earnings growth and margin expansion [8] - Adjusted gross margin for the third quarter was 57.7%, up 240 basis points year-over-year, driven by favorable volume growth and improving portfolio mix [31] - Adjusted operating income for the third quarter was $89.4 million, representing a 25.7% margin, a record for the company [33] Business Line Data and Key Metrics Changes - Hospital revenue grew 24% on a reported basis in the third quarter and 28% year-to-date, with organic growth of 12% and 14% respectively [10] - Blood Management Technologies, the largest hospital franchise, saw revenue growth of 10% in the quarter, driven by sustained market growth and share gains [10] - Hemostasis management experienced 26% revenue growth in the U.S., driven by improved device utilization [11] - Plasma revenue declined 9% in the quarter due to the planned CSL transition, but U.S. disposables revenue grew when excluding CSL [17][22] Market Data and Key Metrics Changes - Revenue growth in Europe for plasma was in double digits, driven by share gains and a robust collections environment [18] - The company signed long-term agreements with BioLife and Grifols, reinforcing its market position and innovation in plasma collections [19][85] - International demand for source plasma is expanding, with the company selected as the exclusive supplier for the Japanese Red Cross [23] Company Strategy and Development Direction - The divestiture of the whole blood business aligns resources to higher margin, higher growth opportunities [9][36] - The company is focused on innovation and technology upgrades to drive market share and improve profitability [20][27] - The updated guidance for hospital revenue is set at 24% to 26% on a reported basis and 12% to 14% on an organic basis [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the foundation being built for transformational growth, despite external market challenges [9][25] - The company anticipates strong earnings performance and has tightened its adjusted EPS guidance range to $4.50 to $4.70 [36] - Management noted that while external disruptions are challenging, the company has adapted and driven progress [26] Other Important Information - Cash on hand at the end of the quarter was $320.8 million, up $142 million since the beginning of the fiscal year [40] - The company expects to finish fiscal '25 with strong free cash flow, updating guidance to a range of $120 million to $140 million [39] Q&A Session Summary Question: Can you walk through the CSL contribution in the quarter? - Management confirmed that CSL's performance is on track with initial guidance, with a 70-30 split in revenue realization [47] Question: What is the outlook for VASCADE? - Management acknowledged competition and internal resource allocation issues but expressed confidence in future performance [60][106] Question: Can you provide details on the BioLife and Grifols contracts? - Management indicated these are long-duration contracts (5 to 7 years) with tiered pricing that benefits both parties [85] Question: What are the expectations for plasma collections growth? - Management anticipates mid to high single-digit growth in fractionation capacity through 2032, indicating a strong market demand [92] Question: How will the divestiture of Whole Blood impact margins? - Management expects a 30 to 40 basis points improvement in operating margin from the divestiture [123]